share_log

华海药业最新公告:拟对华奥泰生物实施第二期员工股权激励

The latest announcement of Huahai Pharmaceutical Co., Ltd.: plans to implement the second phase of employee equity incentive for China Aotai Biology.

證券之星 ·  Jan 20, 2022 03:16

Huahai Pharmaceutical announced that it intends to implement the second phase of employee equity incentive to its subsidiary Huaotai Biology. The incentive targets are the senior managers, core staff and other employees that the company believes should be encouraged in China Aotai Biology and its subsidiaries; the incentive share comes from the 4.6437% equity of Huaotai Biology Company (a total of 20.177732 million shares) transferred by the company to Huaotai Biological employee shareholding platform.

The chairman of the company is Li Hong. Mr. Li Hong: bachelor degree, Deputy Director of Industrial Promotion Center of Ministry of Industry and Information Technology from January 2015 to July 2017; Honorary Advisor of Industrial Promotion Center of Ministry of Industry and Information Technology from August 2017 to December 2017; Strategic Development Advisor of China Biotechnology Co., Ltd and Honorary Advisor of Industrial Promotion Center of Ministry of Industry and Information Technology from January to September 2018 He is currently honorary consultant of the Industrial Promotion Center of the Ministry of Industry and Information Technology, consultant of Jincun Shengshi Pharmaceutical Co., Ltd., and chairman of Zhejiang Huahai Pharmaceutical Co.

This article is compiled by the Securities Star data Center according to the public data and does not constitute investment opinions or suggestions. If you have any questions, please contact us.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment